Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01347307 · ClinicalTrials.gov registry record · NA

Stereotactic Body Radiotherapy for Spine Tumors

A NA study of Meningioma and Chordoma, sponsored by Mercy Research.

Completed
Registry status
NA
Development phase
38
Enrollment target
1
Study location

NCT01347307: Completed NA study of Meningioma and Chordoma, sponsored by Mercy Research.

NCT01347307 is a NA study of Meningioma and Chordoma that has completed, run by Mercy Research. The registered enrollment target is 38 participants, below the 98-participant average among 21 other Meningioma trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01347307, a NA study of Meningioma and Chordoma, has completed, sponsored by Mercy Research.

COMPLETED
Registry status
NA
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of spine metastases and benign spine tumors.

Primary Outcome

Evaluation of pain relief per patient report

Interventions

  • RADIATION SBRT for Benign Extradural Spine Tumors
  • RADIATION SBRT for Vertebral/Paraspinal Metastases

Study Locations (1)

Missouri

  • Mercy Medical Center, St. Louis - St Louis

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2008-09
Est. Completion 2017-09
Phase NA
Mercy Research

14 total trials

What the finished NCT01347307 record still lists

NCT01347307 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 98-participant average among 21 other Meningioma trials with a reported enrollment target (61% lower).

The record links to 9 conditions, with Meningioma appearing as the primary indexed condition, and to 2 interventions - of which SBRT for Benign Extradural Spine Tumors is the first listed.

NCT01347307 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT01347307 about?

NCT01347307 is a clinical study titled "Stereotactic Body Radiotherapy for Spine Tumors". This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of spine metastases and benign spine tumors.

What is the current status of trial NCT01347307?

This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2008-09. Estimated completion is 2017-09.

What conditions does trial NCT01347307 study?

This clinical trial studies the following conditions: Meningioma, Chordoma, Spinal Metastases, Neurofibroma, Schwannoma.

What interventions are being tested in trial NCT01347307?

The interventions under investigation include: SBRT for Benign Extradural Spine Tumors (RADIATION), SBRT for Vertebral/Paraspinal Metastases (RADIATION).

Who is sponsoring clinical trial NCT01347307?

This trial is sponsored by Mercy Research, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01347307 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Meningioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01347307's enrollment target sits among peer trials

38 12th of 21 higher than 10 of 21 other Meningioma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Meningioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01347307, the US trial registry maintained by the National Library of Medicine. NCT01347307 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.